3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Other solid neoplasm
1
Other hematologic neoplasm
1
Myeloid
1
Gastrointestinal
1
Dermatologic
1
CNS
1
Conditions
Carcinoma, Non-Small-Cell Lung
2
Pancreatic Neoplasms
1
Myelodysplastic Syndromes
1
Mesothelioma, Malignant
1
Melanoma
1
Leukemia, Myeloid, Acute
1
Glioblastoma
1
COVID-19
1
Interventions
pembrolizumab
92
Nivolumab
56
Ipilimumab
55
Cyclophosphamide
52
Vemurafenib
28
fludarabine
27
aldesleukin
25
Interleukin-2
25
fludarabine phosphate
21
trametinib
20
dabrafenib
17
Temozolomide
14
Biopsy
14
Cisplatin
13
spartalizumab
12
atezolizumab
12
Carboplatin
11
cobimetinib
10
Specimen Handling
10
Paclitaxel
10
Introns
10
CTLA-4 Antigen
10
poly ICLC
9
binimetinib
9
Radiotherapy
9
Radiosurgery
9
MART-1 Antigen
9
tremelimumab
8
incomplete Freund's adjuvant
8
Radiation
8
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Melanoma
×
bemcentinib
×
Clear all
NCT06469138
2025-01-29
8479217
BerGenBio ASA
Phase 1
Completed
6 enrolled
17 charts